| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1999PNAS...9612719G |
| P356 | DOI | 10.1073/PNAS.96.22.12719 |
| P932 | PMC publication ID | 23066 |
| P698 | PubMed publication ID | 10535989 |
| P5875 | ResearchGate publication ID | 12764642 |
| P2093 | author name string | V E Koteliansky | |
| J George | |||
| D M Bissell | |||
| D Roulot | |||
| P2860 | cites work | Primary structure of human ribosomal protein S14 and the gene that encodes it | Q24299857 |
| The soluble exoplasmic domain of the type II transforming growth factor (TGF)-beta receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-beta ligands | Q24313061 | ||
| Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors | Q24319747 | ||
| TGF beta signals through a heteromeric protein kinase receptor complex | Q24337608 | ||
| Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin | Q24612297 | ||
| Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium | Q24679838 | ||
| Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins | Q24683773 | ||
| The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis | Q28137622 | ||
| Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease | Q28202655 | ||
| Epidemiology of hepatitis C | Q28249543 | ||
| Characterization of type I receptors for transforming growth factor-beta and activin | Q28251169 | ||
| Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction | Q28284617 | ||
| A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate | Q28295474 | ||
| Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis | Q28568136 | ||
| A transforming growth factor beta type I receptor that signals to activate gene expression | Q28576285 | ||
| The role of alpha1beta1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture | Q28580152 | ||
| TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes | Q28592444 | ||
| Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor | Q28631183 | ||
| Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. | Q33632161 | ||
| Cellular distribution of transforming growth factor-beta 1 and procollagen types I, III, and IV transcripts in carbon tetrachloride-induced rat liver fibrosis | Q34252968 | ||
| Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix | Q34257986 | ||
| Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo | Q34263631 | ||
| Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions | Q34480115 | ||
| Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro | Q35610349 | ||
| Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation | Q35750826 | ||
| Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor | Q35997495 | ||
| In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis | Q36220782 | ||
| Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth | Q36351780 | ||
| Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA | Q36351854 | ||
| Cloning, expression, and alternative splicing of the receptor for anti-Müllerian hormone | Q36730528 | ||
| The transforming growth factor beta type II receptor can replace the activin type II receptor in inducing mesoderm | Q36751599 | ||
| Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. | Q37182998 | ||
| Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice | Q37375446 | ||
| Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis | Q37558464 | ||
| Phenotypic stability of adult rat hepatocytes in primary monolayer culture | Q40304653 | ||
| Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease | Q41078715 | ||
| Tumor suppressor activity of the TGF-beta pathway in human cancers | Q41157801 | ||
| Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver fibrogenesis | Q41228197 | ||
| Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor | Q41343795 | ||
| Hepatic stellate cells | Q41368318 | ||
| Collagen types in normal and cirrhotic liver | Q41447374 | ||
| SMADs: mediators and regulators of TGF-beta signaling | Q41732765 | ||
| Basic fibroblast growth factor-induced activation of latent transforming growth factor beta in endothelial cells: regulation of plasminogen activator activity | Q41984680 | ||
| Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation | Q42985387 | ||
| Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta | Q43741134 | ||
| Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix | Q43755354 | ||
| Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix | Q46068321 | ||
| Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues | Q46454375 | ||
| Modulation of transforming growth factor beta receptors of rat lipocytes during the hepatic wound healing response. Enhanced binding and reduced gene expression accompany cellular activation in culture and in vivo. | Q46591125 | ||
| Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1 | Q59066124 | ||
| Deactivation of macrophages by transforming growth factor-β | Q59068031 | ||
| Degradation of newly synthesized collagen | Q67342173 | ||
| Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy | Q67984653 | ||
| Transforming growth factor beta regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts | Q68520119 | ||
| A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections | Q68937846 | ||
| Isolation and culture of hepatic lipocytes, Kupffer cells, and sinusoidal endothelial cells by density gradient centrifugation with Stractan | Q69010783 | ||
| Differential effects of interleukin-1 alpha, tumor necrosis factor alpha, and transforming growth factor beta 1 on cell proliferation and collagen formation by cultured fat-storing cells | Q69737804 | ||
| Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase | Q70370463 | ||
| Contribution of sinusoidal endothelial liver cells to liver fibrosis: expression of transforming growth factor-beta 1 receptors and modulation of plasmin-generating enzymes by transforming growth factor-beta 1 | Q70496879 | ||
| Regulation of extracellular matrix synthesis by transforming growth factor beta 1 in human fat-storing cells | Q70767689 | ||
| Transforming growth factors beta1, beta2, and beta3 and their receptors are differentially regulated during normal and impaired wound healing | Q71070277 | ||
| Transforming growth factor beta 1-regulated gene expression of Ito cells | Q71216112 | ||
| Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers | Q72590540 | ||
| Gene therapy | Q73939993 | ||
| Role of transforming growth factor beta type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats | Q77807982 | ||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 12719-12724 | |
| P577 | publication date | 1999-10-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis | |
| P478 | volume | 96 |
| Q37219104 | 3,3'-Diindolylmethane ameliorates experimental hepatic fibrosis via inhibiting miR-21 expression. |
| Q64376937 | A COL1A1 Promoter-Controlled Expression of TGF-β Soluble Receptor Inhibits Hepatic Fibrosis Without Triggering Autoimmune Responses |
| Q47966770 | A small population of liver endothelial cells undergoes endothelial-to-mesenchymal transition in response to chronic liver injury. |
| Q44566980 | A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury |
| Q40289090 | Active immunization against transforming growth factor beta1 prevents hepatic fibrosis in a rat model of liver disease |
| Q24792944 | Adenoviral expression of a transforming growth factor-beta1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats |
| Q55223894 | Adenovirus‑mediated knockdown of activin A receptor type 2A attenuates immune‑induced hepatic fibrosis in mice and inhibits interleukin‑17‑induced activation of primary hepatic stellate cells. |
| Q75253670 | Advances in alcoholic liver disease |
| Q37353099 | Advances in antifibrotic therapy |
| Q34076187 | Alternative splicing of endothelial fibronectin is induced by disturbed hemodynamics and protects against hemorrhage of the vessel wall |
| Q43263326 | An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells |
| Q33868992 | An herbal formula, CGX, exerts hepatotherapeutic effects on dimethylnitrosamine-induced chronic liver injury model in rats |
| Q36339566 | Anti-TGF-beta strategies for the treatment of chronic liver disease |
| Q36376477 | Antifibrotic agents for liver disease |
| Q36036857 | Antifibrotic therapy in chronic liver disease |
| Q57288769 | Antifibrotics in liver disease: are we getting closer to clinical use? |
| Q35070050 | Attenuation of CCl4-induced hepatic fibrosis in mice by vaccinating against TGF-β1 |
| Q42873630 | Attenuation of N-nitrosodiethylamine-induced liver fibrosis by high-molecular-weight fucoidan derived from Cladosiphon okamuranus |
| Q47208152 | Autocrine release of TGF-beta by portal fibroblasts regulates cell growth |
| Q93647706 | BASL abstracts |
| Q37043515 | Bioconjugation of oligonucleotides for treating liver fibrosis |
| Q34792468 | Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. |
| Q35781240 | Cellular therapies for liver replacement |
| Q43264380 | Chronic intake of a high-cholesterol diet resulted in hepatic steatosis, focal nodular hyperplasia and fibrosis in non-obese mice |
| Q52668406 | Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis. |
| Q24527263 | Cirrhosis: new research provides a basis for rational and targeted treatments |
| Q44419371 | Conditional tetracycline-regulated expression of TGF-β1 in liver of transgenic mice leads to reversible intermediary fibrosis |
| Q37317654 | Current and future anti-fibrotic therapies for chronic liver disease |
| Q30473375 | Current status of novel antifibrotic therapies in patients with chronic liver disease |
| Q33749232 | Differential expression of hepatic fibrosis mediators in sick and spontaneously recovered mice with experimental biliary atresia |
| Q42353109 | Disruption of the Smad7 gene enhances CCI4-dependent liver damage and fibrogenesis in mice |
| Q36855682 | Divergent transforming growth factor-beta signaling in hepatic stellate cells after liver injury: functional effects on ECE-1 regulation |
| Q47785420 | Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis |
| Q43206635 | Effect of compound rhodiola sachalinensis A Bor on CCl4-induced liver fibrosis in rats and its probable molecular mechanisms |
| Q45169698 | Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats |
| Q36410515 | Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection |
| Q41846376 | Effects of TGF-beta1 Ribbon Antisense on CCl(4)-induced Liver Fibrosis |
| Q28576895 | Effects of c-myb antisense RNA on TGF-beta1 and beta1-I collagen expression in cultured hepatic stellate cells |
| Q54590269 | Effects of perindopril and valsartan on expression of transforming growth factor-beta-Smads in experimental hepatic fibrosis in rats. |
| Q46397677 | Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. |
| Q36736835 | Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. |
| Q36478124 | Emerging therapies for liver fibrosis |
| Q36326462 | Enhanced effect of soluble transforming growth factor-beta receptor II and IFN-gamma fusion protein in reversing hepatic fibrosis |
| Q37846143 | Epithelial-mesenchymal interactions in biliary diseases |
| Q37896073 | Exploring anti-TGF-β therapies in cancer and fibrosis. |
| Q35597135 | Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury. |
| Q74505035 | Fibronectin transcription in liver cells: promoter occupation and function in sinusoidal endothelial cells and hepatocytes |
| Q46669947 | Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis |
| Q39586742 | GFAP promoter-driven RNA interference on TGF-β1 to treat liver fibrosis |
| Q37982810 | Hepatic stellate cell progenitor cells |
| Q50578568 | Hepatic stellate cell-specific gene silencing induced by an artificial microRNA for antifibrosis in vitro. |
| Q29616840 | Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver |
| Q35091476 | Hepatitis C and liver fibrosis |
| Q35088302 | Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation |
| Q27316480 | Hepatoprotective effect of MMP-19 deficiency in a mouse model of chronic liver fibrosis |
| Q40644931 | Hyaluronan content in experimental carcinoma is not correlated to interstitial fluid pressure |
| Q38389648 | Hyperoxia accelerates progression of hepatic fibrosis by up-regulation of transforming growth factor-β expression |
| Q40834895 | IFN-gamma gene therapy by intrasplenic hepatocyte transplantation: a novel strategy for reversing hepatic fibrosis in Schistosoma japonicum-infected mice |
| Q38509036 | IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy |
| Q54340131 | Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL4-treated mice. |
| Q39019244 | Immunoregulation by members of the TGFβ superfamily |
| Q41763785 | Increased ΤGF-β3 in primary biliary cirrhosis: An abnormality related to pathogenesis? |
| Q43861531 | Inhibition of dimethylnitrosamine-induced liver fibrosis by [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] (oltipraz) in rats: suppression of transforming growth factor-beta1 and tumor necrosis factor-alpha expression |
| Q64377369 | Inhibitory effect of a soluble transforming growth factor β type II receptor on the activation of rat hepatic stellate cells in primary culture |
| Q42144833 | Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis |
| Q42101278 | Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). |
| Q37375470 | Kupffer cells mediate leptin-induced liver fibrosis |
| Q28486111 | Lack of the matricellular protein SPARC (secreted protein, acidic and rich in cysteine) attenuates liver fibrogenesis in mice |
| Q73158480 | Large scale protein production of the extracellular domain of the transforming growth factor-beta type II receptor using the Pichia pastoris expression system |
| Q44071052 | Leptin is essential for the hepatic fibrogenic response to chronic liver injury |
| Q44624724 | Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis |
| Q41890914 | Liver fibrogenesis due to cholestasis is associated with increased Smad7 expression and Smad3 signaling |
| Q35068035 | Liver fibrosis -- from bench to bedside |
| Q35040127 | Liver in sepsis and systemic inflammatory response syndrome |
| Q45067663 | Liver portal fibrosis in dioxin receptor-null mice that overexpress the latent transforming growth factor-beta-binding protein-1. |
| Q36852793 | Matrix metalloproteinase gene delivery for liver fibrosis |
| Q44765599 | MicroRNA-101 suppresses liver fibrosis by targeting the TGFβ signalling pathway |
| Q39022918 | MicroRNA-19b Expression in Human Biliary Atresia Specimens and Its Role in BA-Related Fibrosis |
| Q64964605 | MicroRNA‑219 overexpression serves a protective role during liver fibrosis by targeting tumor growth factor β receptor 2. |
| Q35649446 | Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ |
| Q28303698 | Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets |
| Q28077583 | Molecular Cues Guiding Matrix Stiffness in Liver Fibrosis |
| Q38806997 | Molecular mechanism of stellate cell activation and therapeutic strategy for liver fibrosis |
| Q40070033 | NEAT1 accelerates the progression of liver fibrosis via regulation of microRNA-122 and Kruppel-like factor 6. |
| Q35628143 | New therapies for chronic hepatitis C virus infection |
| Q46688772 | Of mentors, mentoring, and extracellular matrix |
| Q36401061 | Oral administration of recombinant adeno-associated virus-mediated bone morphogenetic protein-7 suppresses CCl(4)-induced hepatic fibrosis in mice |
| Q58004382 | Parenchymal transforming growth factor beta-1: Its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral etiology |
| Q35607638 | Pathogenesis and management of alcoholic hepatitis. |
| Q40312530 | Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo |
| Q34642580 | Preliminary experimental study of urethral reconstruction with tissue engineering and RNA interference techniques |
| Q34109139 | Progress in systemic sclerosis: novel therapeutic paradigms |
| Q38326327 | Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis |
| Q47118943 | Proteinase-Activated Receptor 2 May Drive Cancer Progression by Facilitating TGF-β Signaling. |
| Q37138893 | Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells - evidence for a role in hepatocellular carcinoma growth in vivo |
| Q43603110 | Regulation of cell growth by redox-mediated extracellular proteolysis of platelet-derived growth factor receptor beta |
| Q34229378 | Regulation of cholangiocyte proliferation |
| Q33583361 | Regulation of fibronectin splicing in sinusoidal endothelial cells from normal or injured liver |
| Q36472048 | Regulation of fibrosis by the immune system |
| Q35621292 | Research progress of vasculopathy in portal hypertension |
| Q37355850 | Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies |
| Q34088326 | Role of alphavbeta6 integrin in acute biliary fibrosis |
| Q46641842 | Signal transduction in alcohol-related diseases |
| Q28567374 | Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization |
| Q46845532 | Smad3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-beta1 in cultured rat hepatic stellate cells |
| Q44507331 | Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats |
| Q45865268 | Soluble TGFbeta type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats |
| Q27640499 | Solution structure of the chick TGFbeta type II receptor ligand-binding domain |
| Q89272035 | Sorafenib and praziquantel synergistically attenuate Schistosoma japonicum-induced liver fibrosis in mice |
| Q34515920 | Suppression of CB1 cannabinoid receptor by lentivirus mediated small interfering RNA ameliorates hepatic fibrosis in rats |
| Q24809810 | TGF beta1 and PDGF AA override collagen type I inhibition of proliferation in human liver connective tissue cells |
| Q42215330 | TGF-beta1 gene silencing for treating liver fibrosis |
| Q38824306 | TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology |
| Q37946756 | TGF-β in progression of liver disease |
| Q39630100 | TGF-β1 mediated activation of Rho kinase induces TGF-β2 and endothelin-1 expression in human hepatic stellate cells |
| Q34322705 | TGFbeta1 in liver fibrosis: time to change paradigms? |
| Q35911123 | Targeted treatments for cirrhosis |
| Q37587875 | Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. |
| Q42591676 | Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy. |
| Q39580698 | Targeting transforming growth factor βRII expression inhibits the activation of hepatic stellate cells and reduces collagen synthesis |
| Q44782829 | The adrenomimetic dobutamine stimulates proliferative activity of hepatocytes and suppresses fibroblasts in mice with posttoxic experimental cirrhosis |
| Q36663411 | The anti-fibrotic effect of bone morphogenic protein-7(BMP-7) on liver fibrosis |
| Q50731057 | The antifibrogenic effect of (-)-epigallocatechin gallate results from the induction of de novo synthesis of glutathione in passaged rat hepatic stellate cells. |
| Q34170449 | The cell and molecular biology of hepatic fibrogenesis. Clinical and therapeutic implications |
| Q38519639 | The flavonoid quercetin inhibits dimethylnitrosamine-induced liver damage in rats |
| Q53621019 | The role of integrin-linked kinase in liver wound healing. |
| Q34832951 | The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells |
| Q41425182 | Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258 |
| Q37352820 | Toll-like receptors, wound healing, and carcinogenesis |
| Q39969437 | Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis |
| Q34563199 | Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats |
| Q24793319 | Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta |
| Q35793352 | Transforming growth factor-beta initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform |
| Q35010511 | Transforming growth factor-beta1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection |
| Q28292776 | Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy |
| Q38073028 | Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies |
| Q35046541 | Treatment of hepatic fibrosis: almost there |
| Q45270334 | Trolox mitigates fibrosis in a bile duct ligation model. |
| Q86382540 | Urethral reconstruction with tissue engineering and RNA interference techniques in rabbits |
| Q42828926 | Ursolic acid, an antagonist for transforming growth factor (TGF)-beta1. |
| Q73405305 | What can be learned about the fibrosis of asthma from rodent models? |
| Q38360649 | Y-box-binding protein YB-1 mediates transcriptional repression of human alpha 2(I) collagen gene expression by interferon-gamma |
| Q73534640 | [Fibrogenesis and liver transplantation] |
| Q78072923 | [Mechanisms of hepatic fibrogenesis] |
| Q77784964 | [New therapeutic strategies in liver fibrosis: pathogenic basis] |
| Q37410984 | αvβ1 integrin as a novel therapeutic target for tissue fibrosis |
Search more.